{
    "clinical_study": {
        "@rank": "99106", 
        "arm_group": {
            "arm_group_label": "Human-cl rhFVIII", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To compare the number of breakthrough bleeds under tailored prophylaxis with human cell line\n      recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients\n      who received Human-cl rhFVIII as on demand treatment."
        }, 
        "brief_title": "Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Haemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Severe Haemophilia A (FVIII:C <1%) according to medical history\n\n          -  Male patients >= 18 year Previous treatment with a FVIII concentrate (regular\n             prophylaxis with good compliance or on-demand treatment) for at least 150 Exposure\n             Days (EDs)\n\n          -  Good documentation regarding dosing and bleeding frequency in the 6 months preceding\n             study start\n\n          -  Immunocompetence (CD4+ count > 200/microliter)\n\n          -  HIV-negative, if positive, viral load <200 particles/microliter or < 400,000\n             copies/mL\n\n        Exclusion Criteria:\n\n          -  Any coagulation disorder other than Haemophilia A\n\n          -  Present or past FVIII inhibitor activity (> 0.6 BU)\n\n          -  Severe liver or kidney disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863758", 
            "org_study_id": "GENA-21"
        }, 
        "intervention": {
            "arm_group_label": "Human-cl rhFVIII", 
            "intervention_name": "Human-cl rhFVIII", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Medical University Vienna"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria"
                    }, 
                    "name": "University Multiprofile Hospital for Active Treatment"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Specialized Hospital for Active Treatment"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Multiprofile Hospital for Active Treatment"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Hungarian National Healthcare Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary"
                    }, 
                    "name": "University of Debrecen, Medical and Health Science Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Sanador SRL"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Timisoara", 
                        "country": "Romania"
                    }, 
                    "name": "Louis Turcanu Emergency Clinical Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "St. Thomas Hosptial"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Bulgaria", 
                "Hungary", 
                "Romania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A", 
        "other_outcome": {
            "measure": "Assess thrombin generation assay in terms of usefulness in individualized therapy", 
            "safety_issue": "No", 
            "time_frame": "7-9 months"
        }, 
        "overall_contact": {
            "email": "sigurd.knaub@octapharma.com", 
            "last_name": "Sigurd Knaub, PhD", 
            "phone": "+41 5541512141"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Paul Ehrlich Institute", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Hungary: National Institute of Pharmacy", 
                "Poland: Office for Registration of medicinal products", 
                "Romania: National Medicines Agency", 
                "Slovakia: State Institute for Drug Control", 
                "Spain:Spanish Agency for Medicine and Health products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction of the annualized total bleeding rate observed in the GENA-01 study (58.1 total bleeding episodes per patient per year) by 50% during individually tailored prophylaxis", 
            "measure": "Reduction of total bleeding rate", 
            "safety_issue": "No", 
            "time_frame": "7-9 months of treatment"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863758"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction of the annualized spontaneous bleeding rate observed in the GENA-01 study (38.5 spontaneous bleeding episodes per patient per year) by 50% during individually tailored prophylaxis", 
                "measure": "Reduction of spontaneous bleeding rate", 
                "safety_issue": "No", 
                "time_frame": "7-9 months"
            }, 
            {
                "description": "Reduction of annualized bleeding rate observed in the GENA-01 study by 50% in patients with 2x/week prophylaxis or less", 
                "measure": "Reduction of bleeding rate", 
                "safety_issue": "No", 
                "time_frame": "7-9 months"
            }
        ], 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}